Mesenchymal stromal cells (MSCs) have demonstrated extensive capacity to modulate a catabolic microenvironment toward tissue repair. The fate, biodistribution, and dwell time of the in vivo delivered MSCs largely depend on the choice of the cell delivery route. Intramuscular (IM) delivery of MSCs is clinically safe and has been used for the effective treatment of local pathologies. Recent findings have shown that the secretome of the IM-delivered MSCs enters the circulation and provides systemic effects on distant organs. In addition, muscle tissue provides a safe residence for the delivered MSCs and an extended secretorily active dwell time compared with other delivery routes. There are, however, controversies concerning the fate of MSCs post IM-delivery and, specifically, into an injured site with proinflammatory cues. This review seeks to provide a brief overview of the fate and efficacy of IM-delivered MSCs and to identify the gaps that require further assessment for adoption of this promising route in the treatment of systemic disease. STEM CELLS TRANSLATIONAL MEDICINE 2019;8:456-465 
INTRODUCTION
Mesenchymal stromal cells [1] have demonstrated extensive capacity to limit injury and promote regeneration through signaling and secretion of trophic factors [2] . Indeed, MSCs provide a putative treatment for immune-related, infectious, and degenerative diseases, without a requirement for engraftment [3] . Despite these beneficial therapeutic effects, one challenge is the short dwell time of the delivered cells in vivo [4] . However, Braid et al. [5] recently reported the extended dwell time of human MSCs (hMSCs) delivered intramuscularly (IM-5 months) in healthy athymic mice when compared with the same cells delivered intravenously (IV-3 days), and either subcutaneously or interperitoneally (3 to 4 weeks). Thus, skeletal muscle provides a putative advantage for MSC delivery.
To date, skeletal muscle has been principally used as a delivery route for local treatment of myopathic, neurodegenerative, and vascular related diseases. However, recent studies have emphasized the opportunity afforded by IMdelivery to effect systemic changes. The 3 main advantages of skeletal muscle MSC delivery are: (a) extended dwell time provided by dense muscle fibers that retain the MSCs in situ; (b) high vascular density that provides a conduit for systemic release of MSC trophic factors; and (c) an abundance of tissue that provides for multiple injection sites. Although the IMdelivery of MSCs has been shown to be clinically safe [6] [7] [8] [9] [10] [11] [12] , it is important to critically evaluate the fate of MSCs postdelivery in skeletal muscle.
Although the trophic factors secreted by MSCs are often considered to have a paracrine or local effect, their release into the blood stream could effect systemic outcomes. We discuss herein the evidence for engraftment and differentiation of IM-delivered MSCs, their secreted factors both local and systemic, their dwell time, and biodistribution.
PRECLINICAL STUDIES: IM-DELIVERED MSCS TO TREAT LOCAL PATHOLOGIES
MSCs have been delivered IM for local treatment or to locally treat complications associated with systemic diseases (Table 2) . These studies have focused predominantly on the local angiogenic and neuro-supportive effects of MSCs although the systemic sequalae of the secreted trophic factors have not been assessed. Diabetic polyneuropathy (DPN), similar to PAD, is a complication associated with diabetes. Shibata et al. [16] IMdelivered rat BMMSCs (rBMMSCs) in streptozotocin (STZ)-induced diabetic Sprague-Dawley (SD) rats. Four weeks postdelivery, the cells were observed in the gaps between the muscle fibers. In addition, a significant increase in the levels of bFGF and vascular endothelial growth factor (VEGF) were observed in the treated muscle. In a similar model in balbC mice, Kim et al. delivered mBMMSCs along the sciatic nerve and reported improvement in motor nerve conduction as early as 2 weeks, whereas no further improvement was observed after 4 weeks [17] . On the other hand, Han et al. [18] delivered allogeneic rBMMSCs in the thigh muscle of DNP-STZ induced Wistar rats near the sciatic nerve, and reported engraftment along the vasa nervosa after 4 and 8 weeks. Additionally, upregulation of angiogenic and neurotrophic genes, myelin protein, and nerve growth factor receptor gene in the transplanted muscle were all observed.
Following their initial use of neural progenitor cells [29] , Suzuki et al. pursued delivery of glial cell derived growth factor (GDNF) transfected MSCs into various muscle groups [19] . In a SD-SOD1
G93A rat model of ALS-that develops neurodegeneration of spinal motor neurons and progressive motor deficits-GDNF hBMMSCs were delivered together with daily cyclosporine (CsA). First, to ameliorate hBMMSC survival, a focal muscle injury was induced with injection of bupivacaine hydrochloride prior to cell delivery. MSC delivery into the muscle led to significant reduction in the number of denervated endplates, and abrogation of motor neuron loss. IM-transplanted MSCs were detected after 8 weeks in the muscle at the site of injection [19] .
In other IM-MSC studies, human cells were xenotransplanted in animal models of CLI for preclinical and translational [24] . Although these studies reported local upregulation of angiogenic growth factors, they showed model-dependent variations in the dwell time of MSCs. Even within a single model differences were seen. For example, Braid et al. [5] showed a 2-log decrease in cells over the first 4 days following IM delivery, although a secretorily active population remained at the injection site for up to 5 months.
IM-DELIVERED MSCS TO TREAT DISTANT AND SYSTEMIC CONDITIONS
MSCs are shown to secrete a plethora of immunomodulatory factors in response to inflammatory stimuli [30] and also to stimulate endogenous cell regeneration [31, 32] . IM-MSC delivery has demonstrated a potential to treat distant or systemic conditions where the long dwell time of secretorily-active cells would provide an advantage over the rapid disappearance of cells from the lungs following IV delivery. The systemic release of the IM-delivered MSC secretome was first demonstrated in 2001 by Bartholomew et al. who showed that human erythropoietin (hEPO) was released for up to 1 month by baboon MSCs, genetically modified to express hEPO, when IM-delivered in NOD/SCID mice [33] . Shabbir et al. IM-delivered porcine BMMSCs (pBMMSCs), two injections 2 weeks apart, into the hamstrings of cardiomyopathic TO2 hamsters. Significant ventricular function improvement (i.e., attenuated chamber dilation) and increased systolic wall thickening were reported 3 weeks after a second IMdelivery of MSCs. MSCs were also shown to reduce apoptosis and myocardial tissue injury, as well as decreased myocardialpathological fibrosis by 50%. The systemic increase in the level of HGF, LIF, and GM-CSF were suggested to be the mediators of myocardial repair, which was concomitant with upregulation of HGF, IGF-II, and VEGF in the myocardium ( [34] ; Table 3 ). Similarly, Zisa et al. IM-delivered hBMMSCs in the hamstrings of TO2 hamsters and reported improved left ventricle ejection fraction (LVEF) by 30%, 4 weeks post-MSC therapy [40] : VEGF was considered to be the main factor that improved cardiac repair. Similarly, Mao et al. IM-delivered human umbilical cord Wharton's jelly MSCs (hWJMSCs) into both fore limb and hind limbs of doxorubicin-induced SD rats (a model of dilated cardiomyopathy), two injections 2 weeks apart. Improved [36] . Furthermore, Liu et al., using human soluble tumor necrosis factor receptor (hsTNFR) transduced hBMMSCs demonstrated a prophylactic reduction in joint inflammation in an antibody-induced/LPS-challenged murine rheumatoid arthritis (RA) model, although the naïve hBMMSCs showed no effect [37] . In another study, Braid et al. showed that a depot of IM-delivered human umbilical cord perivascular cells (HUCPVCs), genetically modified to secrete an antiviral monoclonal antibody, provided systemic protection against exposure to Venezuelan equine encephalitis virus (VEEV), with secretorily active MSCs detectable for 109 days [39] . The engineered HUCPVCs were IM-delivered in the thigh muscle of balbC nu/nu mice 24 hours or 10 days prior to intranasal inoculation with VEEV. No significant difference was observed between 24 hours or 10 days prophylactic protection. We have also IM-delivered hBMMSCs, mBMMSCs, or HUCPVCs in the hind limb of immunocompetent CD1 mice, and reported systemic downregulation of TNF-α and abrogation of neutrophil infiltration at an anatomically distant (contralateral) site of inflammatory injury [38] . These studies provide evidence that factors released from MSCs are the primary therapeutic mediators independent of their engraftment and differentiation at the site of injury and therefore illustrate that IM delivery could be used to treat any condition where a sustained level of circulating mediators secreted by the MSCs would be required. Nevertheless, 3 important factors that affect the efficacy of IM-MSC delivery for a systemic effect are the dwell time of the cells, the cell dose and frequency of injection.
DWELL TIME OF IM-DELIVERED MSCS
The extended dwell time of transplanted MSCs in the skeletal muscle (compared with other routes of administration) enables putative extended therapeutic effects. Nevertheless, the reported dwell time of MSCs delivered to the skeletal muscle varies from 72 hours to 8 months. Two key factors profoundly affect these dwell-time variations: (a) immune-rejection and (b) the methods used for MSC detection. Although autologous MSCs are often used in clinical trials, they can show disease [41] or age-related [42] impairments. Therefore, allotransplantation provides an advantage since MSCs exhibit low immunogenicity, and are expected to evade the immune system. Although the innate immune system is known to contribute to skeletal muscle repair [43] . Davoudi et al. [44] have recently reported that neutrophils and macrophages are scarce in undamaged muscle, which may contribute to the longer dwell time of allogeneic MSCs when compared with lodgment in macrophage-rich lungs following IV delivery. MSCs in vitro exhibit low expression of MHC-I, and costimulatory molecules CD40, B7-1 (CD80), and B7-2 (CD86)-which are involved in T-cell costimulation or coactivation-and lack expression of MHC-II [45] . However, it is not clear whether MSCs maintain their low immunogenicity post-transplantation [20] , especially in an inflamed site. Hemeda et al. demonstrated that MSCs exposed to IFN-γ increased MHC class I expression and also triggered the expression of MHC-II cell surface markers [46] . Ishikane et al. showed a significantly lower number of T-lymphocytes in rBMMSC-transplanted healthy muscle compared with ischemia-induced MSC-transplanted muscle [47] . Even with autologous transplantation, in vitro cell culture expansion conditions may cause phenotypic changes that facilitate innate recognition of the cells when transplanted [48] , resulting in physiological clearance. The only reported preclinical IM-autologous MSC transplantation study, records a dwell time of 6 weeks at the transplanted site [49] , which is significantly less than the dwell time of MSCs in immunocompromised animals. Importantly, even immune-compromised animal models differ in their reaction to xenotransplanted MSCs. Athymic-nude rodents do not produce mature T-cells and have high activity of macrophages, natural killer (NK) and dendritic cells (DC) [50, 51] . In contrast, SCID mice have impaired production of mature T-cells, and severely reduced macrophages NK and DC activity. These factors all affect the dwell time of exogenously transplanted MSCs [25, 27, 52] .
The majority of the preclinical studies are conducted in small animals and MSCs are often allotransplanted. Such studies have shown 17 days to 4 weeks of in situ dwell time [21, 26, 47, 53, 54] , but the length of the study also affects the reported dwell time. A somewhat extended dwell time, ranging from less than 4 to more than 8 weeks, is reported when MSCs are allo-IM transplanted in noninjured muscles in models of systemic conditions such as STZ-induced DPN [16] [17] [18] . MSCs IM-delivered in immunosuppressed (CsA)-rats exhibited a dwell time of 8 weeks when transplanted in a knock out ALS model [19] . It is important to note that CsA blocks recipient Tlymphocyte reactions [28] , and compromises granulocyte migration during acute inflammation. When hMSCs are IMtransplanted in immunocompetent animals, a short dwell time of 4-8 days has been reported by Prather et al. [22] , Francki et al. [23] , and Hamidian Jahromi et al. [38] . Exceptions are the studies by Mao et al. [36] and Shabbir et al. [34] who reported therapeutic effects for 4 weeks that may infer survival of IM-transplanted hWJ-MSC or pBMMSCs in immunocompetent SD-rats and TO2 hamsters respectively, although more probably reflect the "hit-and-run" mechanism by which MSCs are considered to have their effects [55] . On the contrary, some of the studies that have IM-transplanted MSCs in genetically immunocompromised animal models have reported significant dwell times of 3-24 weeks in injured muscle [22, 24, 56] , 4-16 weeks in intact skeletal muscle of animals with systemic disease [37, 39] , and 4-32 weeks in intact healthy animals [5, 33, [57] [58] [59] . One factor that was similar in all reports was the fast decay in cell density over the first 14 days with further decline up to 28 days. For example, Liu et al. [53] transplanted mouse AD-MSCs into the hind limb adductor muscle of ischemic C57BL/6 mice 24 hours postinjury; gradual loss of the IM-transplanted MSCs was reported over 28 days. Ishikane et al. IM-delivered rBMMSCs or rat fetal membrane MSCs (rFM-MSCs) in a CLI model in MHC mismatched rats [47] . Loss of MSC engraftment was observed 3 weeks post IM-MSC delivery with a small quantity of cells still present at the site of injury. The fraction of cells remaining in the muscle for a longer period has been reported to be 10% of the transplanted cells after 8 months [57] .
Suzuki et al. have reported a short MSC dwell time when transplanted into intact muscle. A focal injury in the skeletal muscle, prior to transplantation, extended the MSCs dwelltime [19] . The short dwell time of MSCs in intact muscle does not corroborate the findings of Shibata et al. [ [60] and Braid et al. [5] reported accumulation of MSCs around the site of needle injury which indeed was more pronounced when the density of IM-delivered MSCs declined over time. Although the discussed work does not support the notion of extended dwell time of MSCs in an injured site, it is understood that needle injury itself is a small focal injury created in every IM-delivery model.
CELL DOSE AND FREQUENCY OF INJECTIONS
To date, MSC dosing, both in clinical trials and animal studies has been chosen rather arbitrarily. For IV infusion in humans, 1-2 × 10 6 cells per kilogram body weight is commonly used. As expected for local delivery, lower cell numbers are reported; examples of which are from 1 × 10 6 -10 8 for injection into OA knee joints [61], and 6 × 10 6 cells delivered into the intervertebral disc for the treatment of lower back pain caused by degenerative disc disease [62] . Interestingly, the latter clinical trial showed no therapeutic advantage of using the higher dose, although the clinical study was based, in part, on a sheep study employing both a low 0.5 × 10 6 , and high 4 × 10 6 ovine BMMSCs in which the higher dose was more effective [63] . In an ex vivo pig lung dose escalation study using HUCPVCs, Mordant et al. [64] found a medium dose (5 × 10 7 cells) to be more effective than either a lower or higher dose.
For IM delivery of MSCs, little information is currently available and is contradictory. For example, although Petrou et al. [12] undertook a dose escalation study in patients with ALS (see above), no differential effects of the 3 dosing cohorts of combined IT and IM-delivered autologous BMMSCs were reported. In preclinical studies, Suzuki et al. [19] delivered 0.12 × 10 6 gene-modified human neonatal BMMSCs (see above) either unilaterally or bilaterally into 3 muscle groups (tibialis anterior, triceps brachii, and dorsal trunk musculature) of rats at 24 hours, 1 week, and 2 weeks after local muscle injury. Although the number of surviving cells was reported to increase with multiple injections, no other differences were attributed to the multiple dosing. On the contrary, Kang et al. [65] delivered high and low doses of hBMMSCs in ischemic limbs of Balb/c mice and reported no dose-effect relationship but enhanced results were obtained with higher frequency of MSC injection. Similarly, Mao et al. injected hUCMSCs twice into both fore and hind limb musculature of DCM rats (see above), 2 weeks apart, but reported no differences in outcome with low and high dose (0.25 or 1 × 10 6 cells) although the second treatment did result in significant increase in left ventricular ejection fraction [36] . On the other hand, Shabbir et al. reported that the highest injection dose used, of 0.25, 1, and 4 × 10 6 pBMMSCs into bilateral hamstrings, resulted in the most effective cardiac function improvement in the recipient hamsters [34] .
As all MSCs populations are heterogeneous, but to varying extents, the therapeutically optimum cell dose for a particular delivery route can be expected to vary with MSC tissue source and the therapeutic target condition in addition to variations in the dosing regimen which, for IM administration, can include the number of IM sites chosen, their anatomical location and frequency (for multiple deliveries). Furthermore, gene-modified cells could be expected to be used at different dosing regimens than unmodified populations. Several authors have shown that neonatal MSCs are more potent than those derived from adult tissues including higher MSC frequency, growth rate, life span, and superior immunomodulatory properties [35, [66] [67] [68] [69] [70] [71] [72] .
DIFFERENTIATION OF IM-DELIVERED MSCS
Environmental cues can drive the phenotype of transplanted MSCs. IM-MSC delivery has also been used to treat other local pathologies in local muscle injuries. De Bari et al. [56] , assessed myogenic differentiation of human synovial membrane (hSM)-MSCs-LacZ [26] . Similarly, in a CLI Lewis rat model, Al-Khaldi et al. demonstrated that rBMMSCs transplanted in the ischemic limb of rats express factor VIII, α-SMA actin and desmin, markers of endothelial, smooth muscle and skeletal muscle cells respectively and concluded that the transplanted cells spontaneously regenerated the various components of muscular tissues [21] . Ishikane et al. assessed fusion of MSCs with blood vessel endothelial cells after 1 week of MSC transplantation in the ischemic limb and did not observe GFP+/Lectin double-positive cells [47] which was similar to the reported results of Han et al. observed after 4 and 8 weeks [18] . Studies that did not use specific markers reported that MSCs reside in the gaps between the fibers without differentiation [16, 54] . The collective opinion is that myogenic environmental cues affect the phenotype of exogenously transplanted MSCs, and that this may happen earlier in an injured site.
BIODISTRIBUTION OF MSCS AFTER IM-DELIVERY
The biodistribution of MSCs is important for both safety and survival of MSCs. It is important to assess whether MSCs distribute to unwanted organs postdelivery, cause microembolism, or disappear which could shorten the duration of therapeutic effect. Although it has been shown by many that MSCs can migrate toward the site of injury, this was not demonstrated with the IM-delivery route, except if the injury site was local as shown by Han et al. [18] , who demonstrated a close spatial relationship between IM-delivered BMMSCs and vasa nervora. They considered it likely that the observed increase in angiogenesis Abbreviations: r, rat; m, mouse; h, human; p, porcine; s, sheep; b, baboon; d, day; wk, week; m, month; LIF, leukemia inhibitory factor; GM-CSF, granulocyte-macrophage colony-stimulating factor; cTn1, cardiac troponin 1; HGF, hepatocyte growth factor; VEGF, vascular endothelial growth factor; bFGF, basic fibroblast growth factor; NGF, nerve growth factor; NT-3, neurotrophin-3; GFP, green fluorescent protein; gDNA, genomic DNA; cDNA, complementary DNA; RT-qPCR, reverse transcription polymerase chain reaction; I.S., immunosuppressant.
www.StemCellsTM.com © 2019 The Authors. STEM CELLS TRANSLATIONAL MEDICINE published by Wiley Periodicals, Inc. on behalf of AlphaMed Press was due to both secreted cytokines and physical interaction but provided no evidence for direct cell-cell contact as an effector mechanism. MSCs transplanted in the skeletal muscle are shown to reside locally and secrete trophic factors that enter the systemic circulation. Upon loss of the IM-delivered MSCs from skeletal muscle, either a small (1.5%) portion was found in the liver [57] , or none was observed in any organs other than the muscle site [5, 22-24, 38, 58, 60] . Furthermore, it has been shown that if the needle accidently punctures a major blood vessel, then the IM-delivered MSCs rapidly enter the circulation and transfer into distal organs. This could cause a problem more specifically in small animals that is, mice that exhibit small size muscles.
CONCLUDING REMARKS
The studies reviewed collectively support the notion of broadening the applicability of IM-delivery route from a local therapy to the treatment of systemic disease. Multiple studies have shown that IM-delivered MSCs safely reside in situ for an extended dwell time and are secretorily active. Current assessment of the fate of MSCs post IM-delivery is largely limited to conditions where MSCs are transplanted in an injured site consisting of a significant amount of inflammation. This is a concern, since local injury environmental cues are shown to both impair MSC viability and functionality while driving phenotypic change and lineage differentiation.
This raises many questions, of which the following are examples: What degree of inflammation primes MSCs without affecting their viability and engraftment? What is the degree of inflammation in which MSCs can survive and still exert an immunomodulatory response? and What is the timeframe for a change in MSC phenotype? Answers to these questions are vital in determining the dose of a particular MSC population, and the frequency of their IM-delivery to optimize therapeutic performance.
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